From the archive1 min read
Prevention of acute sickle cell crisis: review of the NEJM report
A recent article in the New England Journal of Medicine presented the results of a phase 2 clinical trial that found positive results for the efficacy and safety of crizanlizumab…
Patient Education · Clinical Trial Studies · Clinical Trials · Complications/Clinical Manifestations · Crizanlizumab/SelG1 · Disease Management · Investigational Therapy/Future Therapy · Pathophysiology · phase II · Sickle Cell Crisis · Vaso-occlusive Crisis/Pain Crisis
About this article
- Source:
- oneSCDvoice(opens in a new tab)
- Published
oneSCDvoice
A recent article in the New England Journal of Medicine presented the results of a phase 2 clinical trial that found positive results for the efficacy and safety of crizanlizumab, a novel pharmaceutical agent currently in pipeline development by Selexys Pharmaceuticals.
The drug, designed to block the underlying mechanism of acute painful crisis in patients suffering from sickle-cell disease, could be one of the first and most effective medications of its kind. For all the details on the Phase 2 research, read the original Practical Pain Management report.
In this commentary, Leonard B. Goldstein, DDS, PhD, and colleagues review the research and provide their own opinion on the prospect of a novel pharmaceutical agents for patients suffering from sickle cell disease.
Abstract source